Search
Interferon alfacon-1
go.drugbank.com/drugs/DB00069ApprovedWithdrawnThe 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding … Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns.
Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTrifarotene
go.drugbank.com/drugs/DB12808ApprovedInvestigational[A187081] Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects … to vitamin A and are analogous only in function.
Anthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalto grow and produce anthrax toxins. … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and
Fencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnIt is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. … It is especially useful in patients with chronic conditions due to its favourable safety profile.
Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigationalExisting inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.
Meningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.
Mixtures: NIMENRIX 0,5 ML IM ENJEKSIYON ICIN TOZ ICEREN FLAKON VE COZUCU ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADETFecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigationalFor this type of therapy to be efficient, qualified donors must be selected. … [A259182,L46217,L46222] Although the incidence of CDI has declined and the number of cases requiring hospitalization has been lower over the years, the recurrence of CDI still represents a challenge.
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigational[A235103,A235118] Amivantamab was found to be more effective than the EGFR inhibitor [erlotinib] or the MET inhibitor [crizotinib] _in vivo_. … [L41469] On December 17, 2025, the U.S.
Elranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigational[L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma. … Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.
Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagerSynonyms: IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN CD3E (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN)), HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE WITH IMMUNOGLOBULIN